{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:33:58Z","timestamp":1791588838555,"version":"4.3.4"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.bcp.2023.115776","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T20:57:00Z","timestamp":1693515420000},"page":"115776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3816-4222","authenticated-orcid":false,"given":"Stefano","family":"Fiorucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Sepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Biagioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Fiorillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Rapacciuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Distrutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Zampella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2023.115776_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2021.101094","article-title":"Bile acids and their receptors in metabolic disorders","volume":"82","author":"Fiorucci","year":"2021","journal-title":"Progress in Lipid Research"},{"key":"10.1016\/j.bcp.2023.115776_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108238","article-title":"Bile acid metabolism and signaling, the microbiota, and metabolic disease","volume":"237","author":"Cai","year":"2022","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.bcp.2023.115776_b0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","article-title":"Bile acid metabolites control T","volume":"576","author":"Hang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2023.115776_b0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","article-title":"The enzymes, regulation, and genetics of bile acid synthesis","volume":"72","author":"Russell","year":"2003","journal-title":"Annual Review of Biochemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0025","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41586-022-04480-z","article-title":"Human gut bacteria produce \u03a4(\u0397)17-modulating bile acid metabolites","volume":"603","author":"Paik","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2023.115776_b0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/164_2019_238","article-title":"The Pharmacology of Bile Acids and Their Receptors","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handbook of Experimental Pharmacology"},{"issue":"5418","key":"10.1016\/j.bcp.2023.115776_b0035","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile Acids: Natural Ligands for an Orphan Nuclear Receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"issue":"5418","key":"10.1016\/j.bcp.2023.115776_b0040","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a Nuclear Receptor for Bile Acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.bcp.2023.115776_b0045","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1073\/pnas.051551698","article-title":"The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity","volume":"98","author":"Staudinger","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5571","key":"10.1016\/j.bcp.2023.115776_b0050","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1126\/science.1070477","article-title":"Vitamin D Receptor As an Intestinal Bile Acid Sensor","volume":"296","author":"Makishima","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bcp.2023.115776_b0055","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.bcp.2023.115776_b0060","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1074\/jbc.M209706200","article-title":"A G protein-coupled receptor responsive to bile acids","volume":"278","author":"Kawamata","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0065","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.29076","article-title":"The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice","volume":"65","author":"Wang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115776_b0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1124\/jpet.102.036376","article-title":"Lithocholylcholine, a bile acid\/acetylcholine hybrid, is a muscarinic receptor antagonist","volume":"303","author":"Cheng","year":"2002","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.bcp.2023.115776_b0075","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000064347","article-title":"Deoxycholic acid conjugates are muscarinic cholinergic receptor antagonists","volume":"65","author":"Raufman","year":"2002","journal-title":"Pharmacology"},{"key":"10.1016\/j.bcp.2023.115776_b0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0014-2999(02)02690-0","article-title":"Selective interaction of bile acids with muscarinic receptors: a case of molecular mimicry","volume":"457","author":"Raufman","year":"2002","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.bcp.2023.115776_b0085","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1073\/pnas.1903316116","article-title":"MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus","volume":"116","author":"Meixiong","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.bcp.2023.115776_b0090","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0095","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/164_2019_227","article-title":"Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.bcp.2023.115776_b0100","doi-asserted-by":"crossref","unstructured":"M.E. Rinella, J. V Lazarus, V. Ratziu, S.M. Francque, A.J. Sanyal, F. Kanwal, D. Romero, M.F. Abdelmalek, Q.M. Anstee, J.P. Arab, M. Arrese, R. Bataller, U. Beuers, J. Boursier, E. Bugianesi, C. Byrne, G.E. Castro Narro, A. Chowdhury, H. Cortez-Pinto, D. Cryer, K. Cusi, M. El-Kassas, S. Klein, W. Eskridge, J. Fan, S. Gawrieh, C.D. Guy, S.A. Harrison, S.U. Kim, B. Koot, M. Korenjak, K. Kowdley, F. Lacaille, R. Loomba, R. Mitchell-Thain, T.R. Morgan, E. Powell, M. Roden, M. Romero-G\u00f3mez, M. Silva, S.P. Singh, S.C. Sookoian, C.W. Spearman, D. Tiniakos, L. Valenti, M.B. Vos, V.W.-S. Wong, S. Xanthakos, Y. Yilmaz, Z. Younossi, A. Hobbs, M. Villota-Rivas, P.N. Newsome, A multi-society Delphi consensus statement on new fatty liver disease nomenclature., Hepatology. (2023). https:\/\/doi.org\/10.1097\/HEP.0000000000000520.","DOI":"10.1097\/HEP.0000000000000520"},{"key":"10.1016\/j.bcp.2023.115776_b0105","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115776_b0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmed.2021.10.005","article-title":"Linking liver metabolic and vascular disease via bile acid signaling","volume":"28","author":"Fiorucci","year":"2021","journal-title":"Trends in Molecular Medicine"},{"issue":"3","key":"10.1016\/j.bcp.2023.115776_b0115","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.clinthera.2021.01.021","article-title":"Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions","volume":"43","author":"Campbell","year":"2021","journal-title":"Clinical Therapeutics"},{"issue":"10","key":"10.1016\/j.bcp.2023.115776_b0120","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/17460441.2021.1916465","article-title":"The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease","volume":"16","author":"Fiorucci","year":"2021","journal-title":"Expert Opinion on Drug Discovery"},{"issue":"10215","key":"10.1016\/j.bcp.2023.115776_b0125","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2023.115776_b0130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/164_2019_237","article-title":"Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists","volume":"256","author":"De Marino","year":"2019","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.bcp.2023.115776_b0135","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/hep4.1720","article-title":"Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis","volume":"5","author":"John","year":"2021","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.bcp.2023.115776_b0140","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/j.bcp.2023.115776_b0145","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep4.1368","article-title":"Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents","volume":"3","author":"Hernandez","year":"2019","journal-title":"Hepatol Commun."},{"key":"10.1016\/j.bcp.2023.115776_b0150","doi-asserted-by":"crossref","DOI":"10.1530\/JME-23-0017","article-title":"A time- and space-resolved nuclear receptor atlas in mouse liver","volume":"71","author":"Zummo","year":"2023","journal-title":"Journal of Molecular Endocrinology"},{"key":"10.1016\/j.bcp.2023.115776_b0155","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.cell.2006.06.049","article-title":"Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network","volume":"126","author":"Bookout","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2023.115776_b0160","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/hep4.1749","article-title":"Meta-analysis and Consolidation of Farnesoid X Receptor Chromatin Immunoprecipitation Sequencing Data Across Different Species and Conditions","volume":"5","author":"Jungwirth","year":"2021","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.bcp.2023.115776_b0165","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/164_2019_232","article-title":"Nonsteroidal FXR Ligands: Current Status and Clinical Applications","volume":"256","author":"Gege","year":"2019","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.bcp.2023.115776_b0170","first-page":"1","article-title":"Recent advances in the development of farnesoid X receptor agonists","volume":"3","author":"Ali","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.bcp.2023.115776_b0175","first-page":"1613","article-title":"Stereoselective synthesis, biological evaluation, and modeling of novel bile acid-derived G-protein coupled Bile acid receptor 1 (GP-BAR1, TGR5) agonists, Bioorganic","volume":"23","author":"Yu","year":"2015","journal-title":"Medicinal Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0180","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1074\/jbc.M115.699504","article-title":"Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet \u03b1 Cells to Promote Glucose Homeostasis","volume":"291","author":"Kumar","year":"2016","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0185","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1021\/jm500889f","article-title":"Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1)","volume":"57","author":"Sepe","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0190","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1021\/jm501273r","article-title":"Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands","volume":"57","author":"Festa","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0195","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1124\/jpet.114.214650","article-title":"Semisynthetic bile acid FXR and TGR5 agonists: physicochemical properties, pharmacokinetics, and metabolism in the rat","volume":"350","author":"Roda","year":"2014","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.bcp.2023.115776_b0200","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/13543776.2018.1459569","article-title":"Farnesoid X receptor modulators 2014-present: a patent review","volume":"28","author":"Sepe","year":"2018","journal-title":"Expert Opinion on Therapeutic Patents"},{"issue":"4","key":"10.1016\/j.bcp.2023.115776_b0205","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1124\/mol.110.064501","article-title":"Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist","volume":"78","author":"Rizzo","year":"2010","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.bcp.2023.115776_b0210","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1681\/ASN.2017020222","article-title":"FXR\/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity","volume":"29","author":"Wang","year":"2018","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"10.1016\/j.bcp.2023.115776_b0215","doi-asserted-by":"crossref","first-page":"12018","DOI":"10.1074\/jbc.C117.794982","article-title":"A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice","volume":"292","author":"Wang","year":"2017","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0220","first-page":"1","article-title":"Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model","volume":"10","author":"Anfuso","year":"2020","journal-title":"Science Reports"},{"issue":"11","key":"10.1016\/j.bcp.2023.115776_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102530","article-title":"The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice","volume":"298","author":"Wang","year":"2022","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0230","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/jm401873d","article-title":"Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors","volume":"57","author":"D\u2019Amore","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"issue":"7","key":"10.1016\/j.bcp.2023.115776_b0235","article-title":"Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling","volume":"10","author":"Cipriani","year":"2015","journal-title":"PLoS One1"},{"key":"10.1016\/j.bcp.2023.115776_b0240","doi-asserted-by":"crossref","DOI":"10.3390\/nu11051132","article-title":"Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation","volume":"11","author":"Carino","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.bcp.2023.115776_b0245","doi-asserted-by":"crossref","first-page":"42801","DOI":"10.1038\/srep42801","article-title":"BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis","volume":"7","author":"Carino","year":"2017","journal-title":"Science Reports"},{"key":"10.1016\/j.bcp.2023.115776_b0250","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41598-023-28647-4","article-title":"Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH","volume":"13","author":"Marchian\u00f2","year":"2023","journal-title":"Science Reports"},{"key":"10.1016\/j.bcp.2023.115776_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2021.805269","article-title":"Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases","volume":"12","author":"Zhang","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.bcp.2023.115776_b0260","first-page":"1","article-title":"Discovery, optimization, and evaluation of non-bile acid FXR\/TGR5 dual agonists","volume":"11","author":"Miyata","year":"2021","journal-title":"Science Reports"},{"key":"10.1016\/j.bcp.2023.115776_b0265","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2337\/db16-0663","article-title":"An Intestinal Farnesoid X Receptor-Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice","volume":"66","author":"Xie","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2023.115776_b0270","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2337\/db11-0030","article-title":"Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity","volume":"60","author":"Prawitt","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2023.115776_b0275","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/ncomms3384","article-title":"Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity","volume":"4","author":"Li","year":"2013","journal-title":"Nature Communications"},{"key":"10.1016\/j.bcp.2023.115776_b0280","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.713149","article-title":"(E)-7-Ethylidene-lithocholic Acid (7-ELCA) Is a Potent Dual Farnesoid X Receptor (FXR) Antagonist and GPBAR1 Agonist Inhibiting FXR-Induced Gene Expression in Hepatocytes and Stimulating Glucagon-like Peptide-1 Secretion From Enteroendocrine Cells","volume":"12","author":"Stefela","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.bcp.2023.115776_b0285","doi-asserted-by":"crossref","first-page":"1140730","DOI":"10.3389\/fonc.2023.1140730","article-title":"Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma","volume":"13","author":"Di Giorgio","year":"2023","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.bcp.2023.115776_b0290","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1073\/pnas.90.4.1440","article-title":"Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor","volume":"90","author":"Gearing","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2023.115776_b0295","first-page":"97","article-title":"Therapies in non-alcoholic steatohepatitis (NASH), Liver Int","volume":"37","author":"Oseini","year":"2017","journal-title":"Off. J. Int. Assoc. Study Liver."},{"key":"10.1016\/j.bcp.2023.115776_b0300","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.biochi.2016.12.019","article-title":"The role and regulation of the peroxisome proliferator activated receptor alpha in human liver","volume":"136","author":"Kersten","year":"2017","journal-title":"Biochimie"},{"key":"10.1016\/j.bcp.2023.115776_b0305","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular Actions of PPAR\u03b1 in Lipid Metabolism and Inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.bcp.2023.115776_b0310","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.neuropharm.2005.02.013","article-title":"Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats","volume":"48","author":"Fu","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2023.115776_b0315","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.prostaglandins.2006.05.002","article-title":"20-carboxy-arachidonic acid is a dual activator of peroxisome proliferator-activated receptors alpha and gamma","volume":"82","author":"Fang","year":"2007","journal-title":"Prostaglandins & Other Lipid Mediators"},{"key":"10.1016\/j.bcp.2023.115776_b0320","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cell.2009.05.036","article-title":"Identification of a physiologically relevant endogenous ligand for PPARalpha in liver","volume":"138","author":"Chakravarthy","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2023.115776_b0325","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1124\/mol.108.051656","article-title":"Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo","volume":"75","author":"Kane","year":"2009","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.bcp.2023.115776_b0330","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11883-020-0823-5","article-title":"Pemafibrate, a New Selective PPAR\u03b1 Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases","volume":"22","author":"Yamashita","year":"2020","journal-title":"Current Atherosclerosis Reports"},{"key":"10.1016\/j.bcp.2023.115776_b0335","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1074\/jbc.274.10.6718","article-title":"Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects","volume":"274","author":"Berger","year":"1999","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0340","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1152\/physrev.00027.2013","article-title":"Physiological functions of peroxisome proliferator-activated receptor \u03b2","volume":"94","author":"Neels","year":"2014","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.bcp.2023.115776_b0345","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.plipres.2016.09.001","article-title":"Transcriptional control of physiological and pathological processes by the nuclear receptor PPAR\u03b2\/\u03b4","volume":"64","author":"Tan","year":"2016","journal-title":"Progress in Lipid Research"},{"key":"10.1016\/j.bcp.2023.115776_b0350","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(03)00269-1","article-title":"Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity","volume":"113","author":"Wang","year":"2003","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bcp.2023.115776_b0355","article-title":"Intestinal PPAR \u03b4 protects against diet-induced obesity, insulin resistance and dyslipidemia","volume":"7","author":"Doktorova","year":"2017","journal-title":"Science Reports"},{"issue":"7","key":"10.1016\/j.bcp.2023.115776_b0360","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.3390\/ijms19071893","article-title":"Insights into the Role of PPAR\u03b2\/\u03b4 in NAFLD","volume":"19","author":"Chen","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.bcp.2023.115776_b0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2021.624112","article-title":"PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action","volume":"12","author":"Hernandez-Quiles","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.bcp.2023.115776_b0370","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1073\/pnas.95.15.8806","article-title":"Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice","volume":"95","author":"Elstner","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.bcp.2023.115776_b0375","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)","volume":"270","author":"Lehmann","year":"1995","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0380","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115776_b0385","first-page":"604","article-title":"Elafibranor for the treatment of NAFLD: One pill, two molecular targets and multiple effects in a complex phenotype","volume":"15","author":"Sookoian","year":"2016","journal-title":"Annals of Hepatology"},{"key":"10.1016\/j.bcp.2023.115776_b0390","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jceh.2022.01.019","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial","volume":"12","author":"Patel","year":"2022","journal-title":"Journal of Clinical and Experimental Hepatology"},{"key":"10.1016\/j.bcp.2023.115776_b0395","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/DMSO.S49592","article-title":"Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence","volume":"8","author":"Sosale","year":"2015","journal-title":"Diabetes. Metab. Syndr. Obes."},{"key":"10.1016\/j.bcp.2023.115776_b0400","doi-asserted-by":"crossref","unstructured":"E. Kotsiliti, Lanifibranor and NASH resolution, Nat. Rev. Gastroenterol. Hepatol. 2021 1812. 18 (2021) 832\u2013832. https:\/\/doi.org\/10.1038\/s41575-021-00544-z.","DOI":"10.1038\/s41575-021-00544-z"},{"key":"10.1016\/j.bcp.2023.115776_b0405","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.bcp.2023.115776_b0410","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/13894501113149990199","article-title":"The first approved agent in the Glitazar\u2019s Class: Saroglitazar","volume":"15","author":"Agrawal","year":"2014","journal-title":"Current Drug Targets"},{"key":"10.1016\/j.bcp.2023.115776_b0415","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bmc.2014.12.013","article-title":"Anthranilic acid derivatives as nuclear receptor modulators\u2013development of novel PPAR selective and dual PPAR\/FXR ligands","volume":"23","author":"Merk","year":"2015","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42004-020-00411-z","article-title":"A triple farnesoid X receptor and peroxisome proliferator-activated receptor \u03b1\/\u03b4 activator reverses hepatic fibrosis in diet-induced NASH in mice","volume":"3","author":"Heitel","year":"2020","journal-title":"Commun. Chem."},{"key":"10.1016\/j.bcp.2023.115776_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117238","article-title":"Discovery of FXR\/PPAR\u03b3 dual partial agonist","volume":"85","author":"Yamashita","year":"2023","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114866","article-title":"Epoxylipids and soluble epoxide hydrolase in heart diseases","volume":"195","author":"Imig","year":"2022","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.bcp.2023.115776_b0435","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1073\/pnas.1422590112","article-title":"Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: role for omega-3 epoxides","volume":"112","author":"L\u00f3pez-Vicario","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.bcp.2023.115776_b0440","doi-asserted-by":"crossref","first-page":"7703","DOI":"10.1021\/acs.jmedchem.7b00398","article-title":"A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis","volume":"60","author":"Schmidt","year":"2017","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0445","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bcp.2019.05.023","article-title":"A dual farnesoid X receptor\/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice","volume":"166","author":"Hye Khan","year":"2019","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.bcp.2023.115776_b0450","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1021\/acsptsci.1c00041","article-title":"Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR\/sEH Modulation in NASH in Diet-Induced Obese Mice","volume":"4","author":"Helmst\u00e4dter","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.bcp.2023.115776_b0455","doi-asserted-by":"crossref","first-page":"9525","DOI":"10.1021\/acs.jmedchem.1c00831","article-title":"Second-Generation Dual FXR\/sEH Modulators with Optimized Pharmacokinetics","volume":"64","author":"Helmst\u00e4dter","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0460","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1021\/acs.jmedchem.8b00458","article-title":"Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology","volume":"61","author":"Schierle","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0465","doi-asserted-by":"crossref","unstructured":"S. De Marino, R. Ummarino, M.V.M.V. V D\u2019Auria, M.G.G.M.G. Chini, G. Bifulco, B. Renga, C. D\u2019Amore, S. Fiorucci, C. Debitus, A. Zampella. Theonellasterols and conicasterols from Theonella swinhoei. Novel marine natural ligands for human nuclear receptors. J Med Chem. 54. (2011). 3065\u20133075. https:\/\/doi.org\/10.1021\/jm200169t.","DOI":"10.1021\/jm200169t"},{"key":"10.1016\/j.bcp.2023.115776_b0470","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1021\/jm101336m","article-title":"Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor","volume":"54","author":"Sepe","year":"2011","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0475","doi-asserted-by":"crossref","first-page":"e30443","DOI":"10.1371\/journal.pone.0030443","article-title":"Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis","volume":"7","author":"Renga","year":"2012","journal-title":"PLoS One1"},{"key":"10.1016\/j.bcp.2023.115776_b0480","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/jm201004p","article-title":"Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei","volume":"55","author":"Sepe","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0485","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.steroids.2012.01.006","article-title":"4-Methylenesterols from Theonella swinhoei sponge are natural pregnane-X-receptor agonists and farnesoid-X-receptor antagonists that modulate innate immunity","volume":"77","author":"De Marino","year":"2012","journal-title":"Steroids"},{"issue":"6","key":"10.1016\/j.bcp.2023.115776_b0490","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.3390\/molecules28062840","article-title":"Expanding the Library of 1,2,4-Oxadiazole Derivatives: Discovery of New Farnesoid X Receptor (FXR) Antagonists\/Pregnane X Receptor (PXR) Agonists","volume":"28","author":"Finamore","year":"2023","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.bcp.2023.115776_b0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166121","article-title":"Liver X receptors and liver physiology","volume":"1867","author":"Russo-Savage","year":"2021","journal-title":"Biochimica et Biophysica Acta \u2013 Molecular Basis of Disease"},{"key":"10.1016\/j.bcp.2023.115776_b0500","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.molmet.2015.01.009","article-title":"The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis","volume":"4","author":"Griffett","year":"2015","journal-title":"Mol. Metab."},{"key":"10.1016\/j.bcp.2023.115776_b0505","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ymgme.2004.07.007","article-title":"T0901317 is a dual LXR\/FXR agonist","volume":"83","author":"Houck","year":"2004","journal-title":"Molecular Genetics and Metabolism"},{"key":"10.1016\/j.bcp.2023.115776_b0510","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.febslet.2007.03.047","article-title":"T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR","volume":"581","author":"Mitro","year":"2007","journal-title":"FEBS Letters"},{"key":"10.1016\/j.bcp.2023.115776_b0515","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/mol.109.060905","article-title":"The benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-alpha\/gamma inverse agonist","volume":"77","author":"Kumar","year":"2010","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.bcp.2023.115776_b0520","doi-asserted-by":"crossref","first-page":"1135952","DOI":"10.3389\/fphar.2023.1135952","article-title":"The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR\/FXR dual receptor activator","volume":"14","author":"Shiragannavar","year":"2023","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.bcp.2023.115776_b0525","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1124\/dmd.121.000455","article-title":"Withaferin A in the Treatment of Liver Diseases: Progress and Pharmacokinetic Insights","volume":"50","author":"Xia","year":"2022","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.bcp.2023.115776_b0530","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1146\/annurev-pharmtox-051921-085014","article-title":"Structures of Leukotriene Biosynthetic Enzymes and Development of New Therapeutics","volume":"63","author":"Haeggstr\u00f6m","year":"2023","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.bcp.2023.115776_b0535","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0006-2952(01)00747-X","article-title":"Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?","volume":"62","author":"Fiorucci","year":"2001","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.bcp.2023.115776_b0540","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/cmdc.202100118","article-title":"Development and in vitro Profiling of Dual FXR\/LTA4H Modulators","volume":"16","author":"Schierle","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bcp.2023.115776_b0545","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1021\/acs.jmedchem.2c01918","article-title":"Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease","volume":"66","author":"Ren","year":"2023","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0550","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd2589","article-title":"Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets","volume":"7","author":"Furuhashi","year":"2008","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.bcp.2023.115776_b0555","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/2211-5463.12240","article-title":"Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease","volume":"7","author":"Mukai","year":"2017","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.bcp.2023.115776_b0560","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1124\/mol.56.3.657","article-title":"Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor","volume":"56","author":"Sarau","year":"1999","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.bcp.2023.115776_b0565","doi-asserted-by":"crossref","first-page":"10967","DOI":"10.1074\/jbc.C113.453704","article-title":"Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand","volume":"288","author":"Kanaoka","year":"2013","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0570","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/med.20071","article-title":"Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends","volume":"27","author":"Capra","year":"2007","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.bcp.2023.115776_b0575","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1100\/tsw.2007.185","article-title":"Cysteinyl-leukotriene receptors and cellular signals","volume":"7","author":"Rovati","year":"2007","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.bcp.2023.115776_b0580","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3748\/wjg.v20.i4.968","article-title":"Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer","volume":"20","author":"Savari","year":"2014","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.bcp.2023.115776_b0585","doi-asserted-by":"crossref","first-page":"18934","DOI":"10.1074\/jbc.M101103200","article-title":"Akt stimulates the transactivation potential of the RelA\/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38","volume":"276","author":"Madrid","year":"2001","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0590","doi-asserted-by":"crossref","first-page":"16512","DOI":"10.1021\/acs.jmedchem.1c01078","article-title":"Structural Basis for Developing Multitarget Compounds Acting on Cysteinyl Leukotriene Receptor 1 and G-Protein-Coupled Bile Acid Receptor 1","volume":"64","author":"Fiorillo","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0595","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.858137","article-title":"Discovery of a Potent and Orally Active Dual GPBAR1\/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease","volume":"13","author":"Fiorucci","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"4","key":"10.1016\/j.bcp.2023.115776_b0600","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1074\/jbc.M608197200","article-title":"Signaling by the cysteinyl-leukotriene receptor 2. Involvement in chemokine gene transcription","volume":"283","author":"Thompson","year":"2008","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.bcp.2023.115776_b0605","doi-asserted-by":"crossref","first-page":"ra93","DOI":"10.1126\/scisignal.2004350","article-title":"Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist","volume":"6","author":"Hennen","year":"2013","journal-title":"Science Signaling"},{"key":"10.1016\/j.bcp.2023.115776_b0610","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/cas.12340","article-title":"5-Lipoxygenase and cysteinyl leukotriene receptor 1 regulate epidermal growth factor-induced cell migration through Tiam1 upregulation and Rac1 activation","volume":"105","author":"Magi","year":"2014","journal-title":"Cancer Science"},{"issue":"22","key":"10.1016\/j.bcp.2023.115776_b0615","doi-asserted-by":"crossref","first-page":"16512","DOI":"10.1021\/acs.jmedchem.1c01078","article-title":"Structural Basis for Developing Multitarget Compounds Acting on Cysteinyl Leukotriene Receptor 1 and G-Protein-Coupled Bile Acid Receptor 1","volume":"64","author":"Fiorillo","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/j.bcp.2023.115776_b0620","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/hep.32787","article-title":"Combinatorial targeting of G-protein-coupled bile acid receptor 1 and cysteinyl leukotriene receptor 1 reveals a mechanistic role for bile acids and leukotrienes in drug-induced liver injury","volume":"78","author":"Biagioli","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2023.115776_b0625","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/13543776.2017.1236918","article-title":"ROR\u03b3 antagonists and inverse agonists: a patent review","volume":"27","author":"Bronner","year":"2017","journal-title":"Expert Opinion on Therapeutic Patents"},{"key":"10.1016\/j.bcp.2023.115776_b0630","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.chembiol.2011.12.011","article-title":"Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity","volume":"19","author":"Burris","year":"2012","journal-title":"Chemistry & Biology"},{"issue":"2","key":"10.1016\/j.bcp.2023.115776_b0635","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4049\/jimmunol.1700183","article-title":"The Bile Acid Receptor GPBAR1 Regulates the M1\/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis","volume":"199","author":"Biagioli","year":"2017","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.bcp.2023.115776_b0640","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1021\/acsomega.2c07907","article-title":"Discovery of a Novel Class of Dual GPBAR1 Agonists-ROR\u03b3t Inverse Agonists for the Treatment of IL-17-Mediated Disorders","volume":"8","author":"Fiorillo","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bcp.2023.115776_b0645","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"key":"10.1016\/j.bcp.2023.115776_b0650","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s42255-023-00812-z","article-title":"Gut hormone co-agonists for the treatment of obesity: from bench to bedside","volume":"5","author":"Nogueiras","year":"2023","journal-title":"Nat. Metab."},{"key":"10.1016\/j.bcp.2023.115776_b0655","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1210\/clinem\/dgab078","article-title":"DPP4 Activity, Hyperinsulinemia, and Atherosclerosis","volume":"106","author":"Love","year":"2021","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.bcp.2023.115776_b0660","doi-asserted-by":"crossref","first-page":"43290","DOI":"10.1038\/srep43290","article-title":"Hyodeoxycholic acid derivatives as liver X receptor \u03b1 and G-protein-coupled bile acid receptor agonists","volume":"7","author":"De Marino","year":"2017","journal-title":"Science Reports"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223003672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223003672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:49:13Z","timestamp":1757771353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223003672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":132,"alternative-id":["S0006295223003672"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115776","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115776"}}